Colorectal Cancer

Colorectal Cancer
2022-01-18T00:00:00.000+00:00
Ongoing

SEAMARK – C4221022

SEAMARK – C4221022
Colorectal cancer

Phase 2, randomized, open-label study of encorafenib and cetuximab plus pembrolizumab versus pembrolizumab alone in participants with previously untreated BRAF V600E-mutant, MSI H/DMMR metastatic colorectal cancer.

Phase 2, randomized, open-label study of encorafenib and cetuximab plus pembrolizumab versus pembrolizumab alone in participants with previously untreated BRAF V600E-mutant, MSI H/DMMR metastatic colorectal cancer.

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Colorectal

Study Phase

II

Trial Identifiers

Registration number: NCT05217446

https://clinicaltrials.gov/study/NCT05217446

GenesisCare Location(s)
North Shore
location pin icon

North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia

phone icon (02) 8037 4100 email icon admin.northshore@genesiscare.com
NSW
North Shore
Principal Investigator(s)
Medical Oncologist

A/Prof. Connie Diakos

BSc (Hons) PhD MBBS FRACP

A/Prof. Connie Diakos
location pin icon

Frenchs Forest (Oncology) +1

View Profile
Profile Image - A/Prof. Connie Diakos

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.